Study on Subcutaneous Talquetamab for Elderly Patients with Early Relapse Multiple Myeloma

Sponsor: Larysa Sanchez

Sponsor score: 0

ClinicalTrials ID:NCT06827860

This clinical trial is testing a new treatment called talquetamab, given as a shot under the skin, for elderly patients with multiple myeloma that has returned after initial treatments. The study aims to find out if this treatment is safe and effective, especially for those who cannot undergo aggressive therapies.

Patient Parameters

Parameter	Options

Program Overview

The study focuses on elderly patients with multiple myeloma, a type of blood cancer, who have experienced an early relapse after initial treatments. Talquetamab is a new type of treatment that helps the body's immune cells target and attack myeloma cells. In earlier studies, talquetamab showed promising results in patients who had already tried many other treatments. This study will evaluate how well talquetamab works and how safe it is for elderly patients. If the cancer continues to progress or does not respond after three cycles of talquetamab, another drug called daratumumab may be added to the treatment plan.

Eligibility Criteria

Inclusion Criteria

Have a confirmed diagnosis of multiple myeloma.
Have measurable disease based on specific lab tests.
Have experienced a return or resistance to previous treatments.
Have received at least two prior lines of therapy, including specific types of drugs.
Be in good enough health to participate, with adequate blood counts and organ function.
Be HIV positive only if the virus is well-controlled.
Agree to use effective birth control methods during the study and for a specified time after.
Be willing to follow study rules and attend all required visits.
Sign a consent form to participate in the study.

Exclusion Criteria

Have severe allergies or reactions to study drugs.
Have received certain types of cancer treatments recently.
Have unresolved side effects from previous cancer treatments.
Have had a stem cell transplant recently.
Have active cancer in the brain or spinal cord.
Have other serious health conditions that could interfere with the study.
Have active infections like hepatitis B or C.
Have uncontrolled diabetes or other serious medical conditions.
Have a history of severe heart problems or recent major surgery.
Plan to father a child during or shortly after the study.

Locations

FACILITY	ZIP	CITY	STATE
Icahn School of Medicine at Mount Sinai	10029	New York	New York

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.